<DOC>
	<DOCNO>NCT01995266</DOCNO>
	<brief_summary>Patients chronic hepatitis genotype 1b , intolerant ineligible Interferon alfa therapy without Ribavirin , treat 24 week Daclatasvir ( DCV ) Dual regimen ( = Daclatasvir + Asunaprevir ) follow additional 24 week post-treatment order determine safety efficacy DCV DUAL regimen</brief_summary>
	<brief_title>Phase III China GT 1b Interferon ( IFN ) Intolerant Prev Exclude Dual</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Males female , ≥ 18 year age Subjects chronically infect HCV Genotype ( GT ) 1b document positive HCV RNA antiHCV antibody screen either : 1 . Positive antiHCV antibody , HCV RNA positive HCV genotype test least 6 month prior screen 2 . Liver biopsy consistent chronic HCV infection ( evidence fibrosis and/or inflammation ) Subjects intolerant previous therapy Interferon Alfa ( IFNα ) either without Ribavirin ( RBV ) ( I±R ) ( independent previous response therapy ) ineligible I±R meet one criterion : 1 . Anemia : I±R intolerants subject previously treat IFNα/RBV therapy decline hemoglobin &lt; 8.5 g/dL therapy ( document ) ; I±R ineligibles subject screen hemoglobin &lt; 10.0 g/dL ≥ 8.5 g/dL OR 2 . Neutropenia : I±R intolerants subject previously treat IFNα/RBV therapy decline absolute neutrophil count ( ANC ) &lt; 0.5 x 10 ( 9 ) therapy ( document ) ; I±R ineligibles subject screen ANC &lt; 1.5 x 10 ( 9 ) cells/L ≥ 0.5 x 10 ( 9 ) cells/L OR 3 . Thrombocytopenia : I±R intolerants subject previously treat IFNα/RBV therapy decline platelet count &lt; 25,000 cells/mm3 therapy ( document ) ; I±R ineligibles subject screen platelet count &lt; 90 x 10 ( 9 ) cells/L ≥ 50 x 10 ( 9 ) cells/L HCV RNA ≥ 10,000 IU/mL Seronegative Human Immunodeficiency Virus ( HIV ) hepatitis B surface antigen ( HBsAg ) Body Mass Index ( BMI ) 18 35 kg/m2 , inclusive . BMI = weight ( kg ) / [ height ( ) ] 2 screening Subjects compensate cirrhosis permit ( compensate cirrhotics cap approximately 40 % ) . If subject cirrhosis , liver biopsy within three year prior enrollment required demonstrate absence cirrhosis . If cirrhosis present , prior liver biopsy sufficient . For country liver biopsy required prior treatment noninvasive imaging test ( Fibroscan® ultrasound ) approve stag liver disease , noninvasive image test result may use assess extent liver disease Prior treatment HCV direct act antiviral ( DAA ) Evidence medical condition contribute chronic liver disease HCV Evidence decompensated liver disease include , limited , history presence ascites , bleed varix , hepatic encephalopathy Diagnosed suspected hepatocellular carcinoma malignancy Uncontrolled diabetes hypertension History moderate severe depression . Wellcontrolled mild depression allow Total bilirubin ≥ 34 µmol/L ( ≥ 2 mg/dL ) unless subject documented history Gilbert 's disease Confirmed alanine aminotransferase ( ALT ) ≥ 5 x upper limit normal ( ULN ) Confirmed albumin &lt; 3.5 g/dL ( 35 g/L ) Alphafetoprotein ( AFP ) &gt; 100 ng/mL OR ≥ 50 ≤ 100 ng/mL require liver ultrasound subject find suspicious hepatocellular carcinoma ( HCC ) exclude Confirmed hemoglobin &lt; 8.5 g/dL Confirmed ANC &lt; 0.5 x 10 ( 9 ) cells/L Confirmed platelet count &lt; 50,000 cells/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>